Monopar Therapeutics (MNPR) Equity Average (2018 - 2020)
Monopar Therapeutics (MNPR) has disclosed Equity Average for 3 consecutive years, with $14.8 million as the latest value for Q3 2020.
- Quarterly Equity Average rose 204.01% to $14.8 million in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $14.8 million through Sep 2020, up 204.01% year-over-year, with the annual reading at $9.8 million for FY2019, 18.19% up from the prior year.
- Equity Average hit $14.8 million in Q3 2020 for Monopar Therapeutics, up from $12.3 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $14.8 million in Q3 2020 to a low of $4.9 million in Q3 2019.
- Historically, Equity Average has averaged $8.9 million across 3 years, with a median of $8.5 million in 2018.
- Biggest five-year swings in Equity Average: crashed 37.88% in 2019 and later skyrocketed 204.01% in 2020.
- Year by year, Equity Average stood at $7.2 million in 2018, then rose by 19.03% to $8.6 million in 2019, then skyrocketed by 71.83% to $14.8 million in 2020.
- Business Quant data shows Equity Average for MNPR at $14.8 million in Q3 2020, $12.3 million in Q2 2020, and $12.5 million in Q1 2020.